Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study

Jeremy S Abramson(Massachusetts General Hospital), M. Lia Palomba(Memorial Sloan Kettering Cancer Center), Leo I. Gordon(Northwestern University), Matthew A. Lunning(University of Nebraska Medical Center), Michael Wang(The University of Texas MD Anderson Cancer Center), Jon Arnason(Beth Israel Deaconess Medical Center), Amitkumar Mehta(University of Alabama at Birmingham), Enkhtsetseg Purev(University of Colorado Denver), David G. Maloney(Fred Hutch Cancer Center), Charalambos Andreadis(University of California, San Francisco), Alison R. Sehgal(UPMC Hillman Cancer Center), Scott R. Solomon(Northside Hospital), Nilanjan Ghosh(Levine Cancer Institute), Tina Albertson(Bristol-Myers Squibb (United States)), Jacob Garcia(Bristol-Myers Squibb (United States)), Ana Kostić(Bristol-Myers Squibb (United States)), Mary Mallaney(Bristol-Myers Squibb (United States)), K. OGASAWARA(Bristol-Myers Squibb (United States)), Kathryn J. Newhall(Bristol-Myers Squibb (United States)), Yeonhee Kim(Bristol-Myers Squibb (United States)), D. Li(Bristol-Myers Squibb (United States)), Tanya Siddiqi(City Of Hope National Medical Center)
The Lancet
September 1, 2020
Cited by 2,304

Abstract


Related Papers

No related papers found

Powered by citation graph analysis